11.03.2022 | Tracker

Product Launch Tracker: Approvals for Boehringer Ingelheim, Eli Lilly, and Novo Nordisk focus of HCP conversations

By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout February 2022 we tracked the global conversations of 2,242 HCPs who posted 3,323 English-language Twitter posts about the launches and approvals of new products.

Graph showing HCP mentions of product launches on Twitter

In February, HCPs continued to share their thoughts on Moderna’s Spikevax, which had been approved by the FDA at the end of the previous month. The other approvals which attracted HCPs attention included another monoclonal antibody treatment for COVID-19 produced by Eli Lilly, an anti-obesity medication from Novo Nordisk, and Boehringer Ingelheim and Eli Lilly’s Jardiance, an SGLT2 inhibitor used to treat heart failure with preserved ejection fraction (HFpEF).

After its FDA approval on 31 January, Moderna’s Spikevax continued to drive HCPs online conversation around product approvals in early February. HCPs continued to share the news that the FDA had changed the status of the COVID-19 vaccine from Emergency Use Authorisation (EUA) to full approval, and assured the public that it is the same vaccine as the EUA version, and is safe to be used.


Additionally, HCPs discussed the FDA’s authorisation of bebtelovimab, a monoclonal antibody manufactured by Eli Lilly for the treatment of the Omicron variant of COVID-19. There was a generally positive consensus for this treatment among HCPs, with one noting it for having an appropriate name for an approval occurring close to valentine’s day.


HCPs also shared the news that the National Institute for Health and Care Excellence (NICE) recommended the drug Wegovy (semaglutide), produced by Novo Nordisk for people living with obesity. The drug, which can be issued via injection, and is designed to help those using it to reduce their weight was welcomed by HCPs, with some suggesting its approval signified a need for change in how health policy approaches obesity, specifically highlighting the ban on coverage of anti-obesity medications.

Another treatment that received a positive reception from HCPs in February was Jardiance (empagliflozin). The treatment, which is co-produced by Boehringer Ingelheim and Eli Lilly was approved by the FDA on 24 February for use in patients with heart failure with a preserved ejection fracture (HFpEF). HCPs celebrated this approval and looked to push for inpatient initiation, alongside outpatient.

Finally, several HCPs also mentioned the FDA’s approval of ViiV healthcare’s product Cabenuva (cabotegravir and rilpivirine), for use every two months to treat HIV. HCPs called the approval “big news” and particularly highlighted it for only needing to be used once every two months instead of monthly.

The three most shared links from HCPs discussing product launches in February were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.



  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 February and 28 February 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 February and 28 February 2022, there were 3,323 HCP mentions of new pharmaceutical product launches and drug approvals from 2,242 unique HCP authors from around the world. 

View the latest and archived product launch trackers here

View all articles >

Meet the Authors

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Tomi Shobande

Tomi is passionate about building relationships with clients and helping them attain their business goals and objectives. With a background in law, international development and human rights, she is keen on bringing about a positive difference around healthcare inequities and shaping health outcomes for all groups.

Tomi enjoys spending good quality time with friends and family. She also is passionate about travel and learning different cultures and histories along the way.

Suggested next

01.10.2020 | Article

Top 50 Pharma Tracker: AstraZeneca’s vaccine trial safety discussed but transparency is celebrated.

Discover what healthcare professionals (HCPs) think about Top 50 pharmaceutical companies

By Mary Kangley

22.07.2022 | Article

Respiratory tracker: HCPs look forward to the COVID-19 booster and flu jab

The topic of conversation that generated excitement and discussion was news about over-50s..

By Mark Sullivan

View all articles >